NO-platform
NO platform allows you to synthesize original hybrid molecules consisting of pharmaceutically active compounds (API), prostaglandins (PG) and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma

Clinical studies

Gurus provides clinical trials in line with GCP standard. For some projects we create R&D alliances with pharmaceutical company or collaborate with venture fund for co-investments. When proof of concept (POC) is shown in clinical trials, Gurus team plans to exit the project through M&A or out-licensing or may decide to develop it further by yourself